Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells

Figure 1 Treatment scheme. BALB/c WT or BALB/c nu/nu mice were injected s.c with 1 × 10⁶ CT-26 cells on Day 7 and were treated with the respective regimens according to the treatment scheme. Group cytokine-induced killer cells (CIK) received two i.v infusions of 4 × 10⁶ CIK cells at a 1-d interval; Group cisplatin (DDP) was treated with DDP (2.5 mg/kg, i.p); Group DDP-CIK was given preconditioning DDP followed by infusions of CIK cells 3 d later; Group normal saline (NS) was treated with normal saline as control.